Department of Psychology, San Diego State University, San Deigo, CA, United States.
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, United States.
J Med Internet Res. 2024 Sep 30;26:e53819. doi: 10.2196/53819.
BACKGROUND: Most new HIV infections are attributed to male-to-male sexual contact in the United States. However, only two-thirds of sexual minority men living with HIV achieve an undetectable viral load (UVL). We tested a web-based antiretroviral therapy adherence intervention called Thrive with Me (TWM) with core features that included medication self-monitoring and feedback, HIV and antiretroviral therapy information, and a peer-to-peer exchange. OBJECTIVE: We assessed the efficacy of TWM on HIV UVL among adult (aged ≥18 years) sexual minority men. Moreover, we assessed the impact of overall engagement and engagement with specific intervention features on HIV UVL. METHODS: In total, 401 sexual minority men (mean age 39.1, SD 10.8 y; 230/384, 59.9% African American) in New York City were recruited between October 2016 and December 2019 and randomized to receive TWM (intervention) or a weekly email newsletter (control) for 5 months. Computerized assessments occurred at baseline and months 5, 11, and 17. The primary outcome was a dichotomous measure of HIV UVL (≤20 copies/μL). Generalized estimating equations with robust SEs were used to assess the effect of the TWM intervention on HIV UVL over the follow-up period in an unadjusted model and a model adjusted for baseline differences and then stratified by baseline recent drug use urinalysis. In secondary analyses, generalized linear models were used to estimate risk differences in the association of overall engagement with TWM (the sum of the number of days participants accessed ≥1 screen of the TWM intervention out of a possible 150 days) and engagement with specific TWM components on HIV UVL throughout the 17-month intervention period. RESULTS: Participant retention was 88.5% (355/401; month 5), 81.8% (328/401; month 11), and 80.3% (322/401; month 17). No consistent differences in HIV UVL were found between those randomized to receive TWM or the control at the 5- (difference-in-differences [DD]=-7.8, 95% CI -21.1 to 5.5), 11- (DD=-13.9, 95% CI -27.7 to 0.04), or 17-month (DD=-8.2, 95% CI -22.0 to 5.7) time points, or when stratified by baseline recent drug use. However, those TWM-assigned participants with high overall levels of engagement (in the upper 25th percentile) were more likely to have an HIV UVL at the end of the 5-month active intervention period compared to those with low engagement (below the 75th percentile; risk difference=17.8, 95% CI 2.5-33.0) or no engagement (risk difference=19.4, 95% CI 3.3-35.5) in the intervention. Moreover, high engagement with the peer-to-peer exchange was associated with HIV UVL over time in unadjusted models. CONCLUSIONS: TWM did not have overall impacts on HIV UVL; however, it may assist some sexual minority men who are highly engaged with this web-based intervention in achieving HIV viral suppression. TRIAL REGISTRATION: ClinicalTrials.gov NCT02704208; https://clinicaltrials.gov/study/NCT02704208.
背景:在美国,大多数新的 HIV 感染可归因于男男性接触。然而,只有三分之二的 HIV 阳性的性少数群体男性实现了无法检测到的病毒载量(UVL)。我们测试了一种名为“与我共同成长”(TWM)的基于网络的抗逆转录病毒治疗依从性干预措施,该措施具有包括药物自我监测和反馈、HIV 和抗逆转录病毒治疗信息以及同伴交流等核心功能。
目的:评估 TWM 对成年(年龄≥18 岁)性少数群体男性 HIV UVL 的疗效。此外,我们评估了总体参与度以及对特定干预措施特征的参与度对 HIV UVL 的影响。
方法:2016 年 10 月至 2019 年 12 月,我们在纽约市招募了 401 名性少数群体男性(平均年龄 39.1±10.8 岁;230/384,59.9%为非裔美国人),并将他们随机分配接受 TWM(干预组)或每周电子邮件通讯(对照组),为期 5 个月。在基线和第 5、11 和 17 个月进行计算机评估。主要结局是 HIV UVL(≤20 拷贝/μL)的二分测量值。使用广义估计方程和稳健标准误差来评估 TWM 干预对随访期间 HIV UVL 的影响,在未调整模型和调整基线差异后,然后按基线近期尿液药物分析分层。在次要分析中,使用广义线性模型估计整体参与 TWM(参与者访问 TWM 干预≥1 个屏幕的天数总和除以可能的 150 天)与参与特定 TWM 组件与 HIV UVL 的关联的风险差异整个 17 个月的干预期。
结果:参与者的保留率为 88.5%(355/401;第 5 个月)、81.8%(328/401;第 11 个月)和 80.3%(322/401;第 17 个月)。在第 5、11 和 17 个月时,与接受 TWM 或对照组的参与者相比,HIV UVL 没有发现一致的差异(差值差异[DD]=-7.8,95%置信区间-21.1 至 5.5),或分层按基线近期药物使用。然而,那些总体参与度较高(处于上 25%百分位)的 TWM 分配参与者在 5 个月的积极干预期结束时更有可能达到 HIV UVL,而那些参与度较低(低于 75%百分位)或没有参与度(风险差异=17.8,95%置信区间 2.5-33.0)的参与者相比。此外,在未调整模型中,高参与度与同伴交流与 HIV UVL 随时间的变化有关。
结论:TWM 对 HIV UVL 没有总体影响;然而,它可能会帮助一些高度参与这项基于网络的干预措施的性少数群体男性实现 HIV 病毒抑制。
试验注册:ClinicalTrials.gov NCT02704208;https://clinicaltrials.gov/study/NCT02704208。
Cochrane Database Syst Rev. 2008-7-16
Cochrane Database Syst Rev. 2014-5-22
Cochrane Database Syst Rev. 2010-3-17
Cochrane Database Syst Rev. 2015-2-18
Curr HIV/AIDS Rep. 2023-12
J Am Med Inform Assoc. 2023-2-16